ResearcherSorbonne UniversitéActive in the last 2 years
Mathilde Wagner
Matched on ORCID iD 0000-0003-1172-4592; OpenAlex author ID A5018325341. Sources: ClinicalTrials.gov.
Their work
- Papers
- 4 (first author 1, last author 0)
- Trials
- 1 (principal investigator on 1)
- Grants
- 0
- Labs led
- 0
- Collaborators
- 23
2015: 1 paper · 2016: none · 2017: 1 paper, 1 trial · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper
Papers 4
- Correlation between circulating tumor DNA quantity assessed by methylated markers and tumor volume in patients with metastatic pancreatic adenocarcinoma. First author DOI 10.1038/s41598-025-13160-7↗
- Splenic vein tumor thrombosis is a major prognostic factor in distal pancreatic adenocarcinoma. Co-author DOI 10.1016/j.surg.2023.10.028↗
- CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. Co-author DOI 10.1007/s00330-016-4632-8↗
- Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-… Co-author DOI 10.1245/s10434-015-4783-x↗
Trials 1
Closest collaborators
The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jean‐Baptiste Bachet · 4 shared papers, 2015–2025 · strength 0.56
- Paper Correlation between circulating tumor DNA quantity assessed by methylated markers and tumor volume in patients with met… DOI 10.1038/s41598-025-13160-7↗
- Paper Splenic vein tumor thrombosis is a major prognostic factor in distal pancreatic adenocarcinoma. DOI 10.1016/j.surg.2023.10.028↗
- Paper CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. DOI 10.1007/s00330-016-4632-8↗
- Daniel Pietrasz · 3 shared papers, 2015–2025 · strength 0.38
- Paper Correlation between circulating tumor DNA quantity assessed by methylated markers and tumor volume in patients with met… DOI 10.1038/s41598-025-13160-7↗
- Paper CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. DOI 10.1007/s00330-016-4632-8↗
- Paper Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Adva… DOI 10.1245/s10434-015-4783-x↗
- António Sá Cunha · 3 shared papers, 2015–2024 · strength 0.29
- Paper Splenic vein tumor thrombosis is a major prognostic factor in distal pancreatic adenocarcinoma. DOI 10.1016/j.surg.2023.10.028↗
- Paper CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. DOI 10.1007/s00330-016-4632-8↗
- Paper Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Adva… DOI 10.1245/s10434-015-4783-x↗
- Olivier Caliez · 1 shared paper, 2025 · strength 0.27
- Léo Mas · 1 shared paper, 2025 · strength 0.27
- Pierre Laurent‐Puig · 1 shared paper, 2025 · strength 0.27
- Solène Doat · 1 shared paper, 2025 · strength 0.27
- Patrick Pessaux · 1 shared paper, 2024 · strength 0.18
- Sébastien Gaujoux · 1 shared paper, 2024 · strength 0.18
- Gerlinde Avérous · 1 shared paper, 2024 · strength 0.18
- Alain Sauvanet Sauvanet · 1 shared paper, 2024 · strength 0.18
- Ugo Marchèse · 1 shared paper, 2024 · strength 0.18
- Florence Jeune · 1 shared paper, 2024 · strength 0.18
- Christophe Cassinotto · 1 shared paper, 2017 · strength 0.07
- Jean‐Frédéric Blanc · 1 shared paper, 2015 · strength 0.04
- Olivıer Turrini · 1 shared paper, 2015 · strength 0.04
- Christophe Laurent · 1 shared paper, 2015 · strength 0.04
- Lysiane Marthey · 1 shared paper, 2015 · strength 0.04
- Isabelle Trouilloud · 1 shared paper, 2015 · strength 0.04
- Olivia Hentic Dhome · 1 shared paper, 2015 · strength 0.04
- Julien Taı̈eb · 1 shared paper, 2015 · strength 0.04
- Jean‐Luc Raoul · 1 shared paper, 2015 · strength 0.04
- Romain Coriat · 1 shared paper, 2015 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.